Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

PR Newswire associated2

PR Newswire associated3

Tags

Piramal-IntoCell

More Like This

PR Newswire associated0

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

PR Newswire associated0

PIRAMAL PHARMA SOLUTIONS COMMEMORATES OPENING OF ITS ADC MANUFACTURING EXPANSION IN GRANGEMOUTH, SCOTLAND

PR Newswire associated0

Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site

PR Newswire associated0

Piramal Pharma Ltd. Continues to Invest In USA; $90M in Expansions of Two US Sites

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

PR Newswire associated0

Piramal Pharma Solutions Achieves Revenue Threshold on Innovation Work

PR Newswire associated0

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco.

SK pharmteco and LOTTE BIOLOGICS Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities